It is predicted that there will be a global increase in late adulthood morbidity
(West and Sommer, 2001), with population estimates indicating a
rise in age related maculopathy in the over 75 years age group (Klein et al.,
2002, 2004). AMD already accounts for 50 per cent of blind registrations
(Klein et al., 2002), the trend suggesting further exploration of the health
needs of this client group.